AstraZeneca Appoints Dr. Susan Galbraith as Executive Vice President, Oncology Research & Development
- Date 7 Jul 2021
AstraZeneca today appointed Dr. Susan Galbraith to lead Oncology Research & Development from initial discovery through late-stage development. Her appointment follows the passing of José Baselga earlier this year. She will join the Company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot.
Susan previously led early-stage Oncology R&D, overseeing the successful progression of seven programmes into Phase III trials, with four new medicines now approved in countries around the world. During this time, she played a pivotal role in the evolution of AstraZeneca’s Oncology strategy, supporting pioneering research, embracing cutting-edge technologies and forging successful partnerships to transform productivity and scientific output.
You might also be interested in these articles
A Global Centre for DeepTech Innovation: Cambridge Future Tech Welcomes Japanese Minister of State to The Park
Sun 12 May 2024
Cambridge Science Park
Steaming up Success: ARU student’s path from café to creativity
We recently did a Q&A session with Anglia Ruskin student Soorya Jith, who started his journey as a Barista at the Lakeside Café within the Bradfield Centre on Cambridge Science Park. He has now transitioned to Krank, also located on the Park, as a Junior Graphic Designer.
Sun 21 Apr 2024
Cambridge Science Park
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
